Van Der Valk, Mirthe Emilie; Mangen, Marie Josée J; Leenders, Max; Dijkstra, Gerard; Van Bodegraven, Ad A.; Fidder, Herma H.; De Jong, Dirk J.; Pierik, Marieke; Van Der Woude, C. Janneke; Romberg-Camps, Mariëlle J L; Clemens, Cees H M; Jansen, J.M.; Mahmmod, Nofel; Van De Meeberg, Paul C.; Van Der Meulen-De Jong, Andrea E.; Ponsioen, Cyriel Y.; Bolwerk, Clemens J M; Vermeijden, J. Reinoud; Siersema, Peter D.; Van Oijen, Martijn G H; Oldenburg, Bas
(BMJ Publishing Group, 2014)
Objective The introduction of anti tumour necrosis factor-α (anti-TNFα) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) following the ...